Drugs / TEZ/IVA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03224351 | Aug 2017 → Feb 2018 | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-10-18 | Vertex Pharmaceuticals Incorporated | Results Vertex Data Presented at North American Cystic Fibrosis Conference (NACFC) Demonstrate Rapid Progress Toward Expanding and Enhancing Options for Treating the Underlying Cause of Cystic Fibrosis vrtx.com ↗
Phase 2 results of VX-659 and VX-445 triple combination regimens concurrently published in The New England Journal of Medicine |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-10-18 | Vertex Pharmaceuticals Incorporated | Vertex Data Presented at North American Cystic Fibrosis Conference (NACFC) Demonstrate Rapid Progress Toward Expanding and Enhancing Options for Treating the Underlying Cause of Cystic Fibrosis vrtx.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TEZ/IVA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03224351 ↗ |
| Action | Restore | “developed to restore the function of Phe508del CFTR protein” PMID 30334693 ↗ Oct 2018 |
| Route | Oral | “TEZ/IVA fixed-dose combination tablet for oral administration.” NCT03224351 ↗ |
| Target | CFTR | “restore the function of Phe508del CFTR protein” PMID 30334693 ↗ Oct 2018 |